Skip to content
Biodatica
Start free

Institut Cancerologie de l'Ouest

Angers

OncologyGrant-only
Compare Sign in to watch

What changed

Study registered, no phase assigned: Stereotactic Radiotherapy for SPinal Metastases With Limited Extent of Epidural Disease

4w agoTrial registeredJun 18, 2026Source filing (opens the source filing in a new tab)

Momentum

79no change

Momentum 79 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

9,379 pre-ticker oncology companies at Grant-only

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    NA registered

    Oct 1, 2026

    Epiduritis, Vertebral Bone Metastasis · NOT_YET_RECRUITING · sponsor: Institut Cancerologie de l'Ouest · Stereotactic Radiotherapy for SPinal Metastases With Limited Extent of Epidural Disease

    ClinicalTrials.gov · NCT07656883 (opens the source filing in a new tab)

  2. Trial

    NA registered

    Jun 1, 2026

    Prostate Cancer Metastatic Disease, Oligometastatic Prostate Cancer (OMPC) · RECRUITING · sponsor: Institut Cancerologie de l'Ouest · HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymph Node Metastases (HIMARS)

    ClinicalTrials.gov · NCT06978296 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources